What is the B7-33 dosage, and how is it mixed?
Every vial at a glance.
| Vial | 1 mL of water | 2 mL of water |
|---|---|---|
| 5 mg | 5 mg/mL: 500 mcg is 10 units, 1,000 mcg is 20 units | 2.5 mg/mL: 500 mcg is 20 units, 1,000 mcg is 40 units |
| 10 mg | 10 mg/mL: 500 mcg is 5 units, 1,000 mcg is 10 units | 5 mg/mL: 500 mcg is 10 units, 1,000 mcg is 20 units |
No label or human trial gives a B7-33 dose; one mouse study gave 0.25 mg/kg/day under the skin (Alam and colleagues, 2023), which is animal data and not a human dose.1
Is there a label, vial strength or mixing instruction?
The table is arithmetic on example vial sizes, water volumes and doses; none of them is a B7-33 figure from a source.
A search of DailyMed and ClinicalTrials.gov found no label or approved product for B7-33. The EMA's CHMP gave a negative opinion on serelaxin (Reasanz), the parent hormone, on 23 January 2014 and confirmed the refusal of marketing authorisation on 22 May 2014; that is not a B7-33 label.2
A search for B7-33 vial strengths found only vendor pages, no maker leaflet or regulator page. With no sourced concentration, there is no sourced way to turn a dose into a volume or a U-100 syringe mark. Reconstitution instructions were not found in DailyMed or on the web either.
Dose and schedule on record
No label found in DailyMed or at the EMA states a dose for B7-33 or relaxin. The parent hormone, serelaxin, was given in RELAX-AHF-2 (NCT01870778), a phase III trial of 6600 acute heart failure patients, as a continuous intravenous infusion of 30 ug/kg/day for 48 hours, against a matching placebo infusion.3 That is serelaxin and not B7-33, so no B7-33 dose follows from it.
What the mouse studies gave
The B7-33 doses on record are mouse doses by injection or by mouth, not human doses.451
| Study | B7-33 dose, route and schedule in mice |
|---|---|
| Devarakonda and colleagues, 2020 | twice a day, 0.25 mg/kg per dose, once every 12 hours, against saline4 |
| Alam and colleagues, 2023 | 0.25 mg/kg/day subcutaneously on days 7 to 14 after isoprenaline injury in adult male mice, beside relaxin 0.5 mg/kg/day and perindopril 1 mg/kg/day1 |
| Somanader-Livera and colleagues, 2025 | 25 ng/day by mouth, unconjugated or nanoparticle-conjugated, (7 mice per group), beside perindopril 60 ng/day5 |
Storage and stability
No storage conditions before or after mixing were found in a label, maker leaflet or stability data. The stability figure found is laboratory serum data: the authors report a half-life of about 6 minutes in vitro for B7-33 (60 minutes for a lipidated analogue), which is neither a human figure nor a shelf life.6
Frequently asked questions
Is B7-33 on the WADA list?
The WADA list text found does not name B7-33 or relaxin. Its class S0 prohibits at all times any pharmacological substance not addressed by the list's other sections and with no current approval by any governmental regulatory health authority for human therapeutic use, such as drugs under pre-clinical or clinical development.7
Is there a registered clinical trial of B7-33?
A ClinicalTrials.gov search for B7-33 as an intervention returned no studies.
References
- PubMed. The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy. 2023. pubmed.ncbi.nlm.nih.gov
- EMA. Reasanz | European Medicines Agency (EMA). ema.europa.eu
- ClinicalTrials.gov. NCT01870778: Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF. 2018. clinicaltrials.gov
- PubMed Central. B7‐33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction–Related Adverse Cardiac Remodeling in Mice. 2020. pmc.ncbi.nlm.nih.gov
- PubMed Central. Immune cell uptake of glycinated nanoparticles conjugated to anti-fibrotic peptides enables their prolonged activity and oral administration. 2025. pmc.ncbi.nlm.nih.gov
- PubMed Central. A Lipidated Single-B-Chain Derivative of Relaxin Exhibits Improved In Vitro Serum Stability without Altering Activity. 2023. pmc.ncbi.nlm.nih.gov
- WADA. WORLD ANTI-DOPING CODE. wada-ama.org